1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Pathology: Mechanisms of Disease
  4. Volume 17, 2022
  5. Article

Annual Review of Pathology: Mechanisms of Disease

Volume 17, 2022

Precision Medicine in Low- and Middle-Income Countries

Abstract

Most cancer cases occur in low- and middle-income countries (LMICs). The sophisticated technical and human infrastructure needed for optimal diagnosis, treatment, and monitoring of cancers is difficult enough in affluent countries; it is especially challenging in LMICs. In Western, educated, industrial, rich, democratic countries, there is a growing emphasis on and success with precision medicine, whereby targeted therapy is directed at cancers based on the specific genetic lesions in the cancer. Can such precision approaches be delivered in LMICs? We offer some examples of novel partnerships and creative solutions that suggest that precision medicine may be possible in LMICs given heavy doses of will, creativity, and persistence and a little luck.

Keyword(s): diagnostics, LMICs, precision medicine
Loading

Article metrics loading...

/content/journals/10.1146/annurev-pathol-042320-034052
2022-01-24
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/pathmechdis/17/1/annurev-pathol-042320-034052.html?itemId=/content/journals/10.1146/annurev-pathol-042320-034052&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Lancet 2018. GLOBOCAN 2018: counting the toll of cancer. Lancet 392:10152985
     [Google Scholar]
  2. 2. 
    WHO (World Health Organ.) 2019. Second WHO model list of essential in vitro diagnostics Publ. WHO/MVP/EMP/2019.05 WHO Geneva:
  3. 3. 
    Nelson AM, Milner DA, Rebbeck TR, Iliyasu Y. 2016. Oncologic care and pathology resources in Africa: survey and recommendations. J. Clin. Oncol. 34:120–26
     [Google Scholar]
  4. 4. 
    Neal RD, Tharmanathan P, France B, Din NU, Cotton S et al. 2015. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br. J. Cancer 112:Suppl. 1S92–107
     [Google Scholar]
  5. 5. 
    WHO (World Health Organ.). Cancer Fact Sheet 2020 Geneva: WHO https://www.who.int/news-room/fact-sheets/detail/cancer
  6. 6. 
    WHO (World Health Organ.) 2017. Guide To Cancer Early Diagnosis Geneva: WHO
  7. 7. 
    Drake TM, Knight SR, Harrison EM, Soreide K 2018. Global inequities in precision medicine and molecular cancer research. Front. Oncol. 8:346
     [Google Scholar]
  8. 8. 
    Luu MH, Press RD. 2013. BCR–ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring. Expert Rev. Mol. Diagn. 13:7749–62
     [Google Scholar]
  9. 9. 
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349:151423–32
     [Google Scholar]
  10. 10. 
    Hughes T, Deininger M, Hochhaus A, Branford S, Radich J et al. 2006. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:128–37
     [Google Scholar]
  11. 11. 
    Branford S, Yeung DT, Ross DM, Prime JA, Field CR et al. 2013. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:193818–24
     [Google Scholar]
  12. 12. 
    Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C et al. 2013. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:4515–22
     [Google Scholar]
  13. 13. 
    Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N et al. 2006. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:101767–73
     [Google Scholar]
  14. 14. 
    Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R et al. 2012. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 119:81838–43
     [Google Scholar]
  15. 15. 
    Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F et al. 2010. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:111029–35
     [Google Scholar]
  16. 16. 
    Malhotra H, Radich JP, Garcia-Gonzalez P. 2019. Meeting the needs of CML patients in resource-poor countries. Hematolology 2019: American Society of Hematology Education Program433–42 Washington, DC: Am. Soc. Hematol.
     [Google Scholar]
  17. 17. 
    Sala Torra O, Beppu L, Smith JL, Welden L, Georgievski J et al. 2016. Paper or plastic? BCR-ABL11 quantitation and mutation detection from dried blood spots. Blood 127:222773–74
     [Google Scholar]
  18. 18. 
    Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J et al. 2007. Development of an integrated assay for detection of BCR-ABL RNA. Clin. Chem. 53:91593–600
     [Google Scholar]
  19. 19. 
    Qiagen 2016. QIAamp® DNA mini and blood mini handbook Handb. Qiagen Germantown, MD:
  20. 20. 
    Laurent C, Baron M, Amara N, Haioun C, Dandoit M et al. 2017. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. J. Clin. Oncol. 35:182008–17
     [Google Scholar]
  21. 21. 
    Strobbe L, van der Schans SAM, Heijker S, Meijer JWR, Mattijssen EJMV et al. 2014. Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. Leuk. Lymphoma 55:51018–22
     [Google Scholar]
  22. 22. 
    Valvert F, Silva O, Solórzano-Ortiz E, Puligandla M, Siliézar Tala MM. et al. 2021. Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countries. Blood Adv. 5:102447–55
     [Google Scholar]
  23. 23. 
    Salles G, Barrett M, Foa R, Maurer J, O'Brien S et al. 2017. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv. Ther. 34:102232–73
     [Google Scholar]
  24. 24. 
    Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M et al. 2019. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393:10168229–40
     [Google Scholar]
  25. 25. 
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136:5E359–86
     [Google Scholar]
  26. 26. 
    Gakwaya A, Kigula-Mugambe JB, Kavuma A, Luwaga A, Fualal J et al. 2008. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br. J. Cancer 99:163–67
     [Google Scholar]
  27. 27. 
    Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS et al. 2010. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 11:2165–73
     [Google Scholar]
  28. 28. 
    DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A 2015. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol. Biomarkers Prev. 24:101495–506
     [Google Scholar]
  29. 29. 
    Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT et al. 2020. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. Int. J. Cancer 146:51208–18
     [Google Scholar]
  30. 30. 
    Foerster M, Anderson BO, McKenzie F, Galukande M, Anele A et al. 2019. Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study. Breast Cancer Res. 21:193
     [Google Scholar]
  31. 31. 
    Anderson BO, Carlson RW. 2007. Guidelines for improving breast health care in limited resource countries: the Breast Health Global Initiative. J. Natl. Compr. Cancer Netw. 5:3349–56
     [Google Scholar]
  32. 32. 
    Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP et al. 2014. International adaptations of NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 12:5643–48
     [Google Scholar]
  33. 33. 
    Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS et al. 2008. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer 113:8 Suppl2269–81
     [Google Scholar]
  34. 34. 
    Shyyan R, Sener SF, Anderson BO, Garrote LM, Hortobagyi GN et al. 2008. Guideline implementation for breast healthcare in low- and middle-income countries: diagnosis resource allocation. Cancer 113:Suppl. 82257–68
     [Google Scholar]
  35. 35. 
    WHO Expert Comm. Sel. Use Essent. Med 2014. The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children) WHO Tech. Rep. Ser. No. 985 WHO Geneva:
  36. 36. 
    Bird PA, Hill AG, Houssami N. 2008. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann. Surg. Oncol. 15:71983–88
     [Google Scholar]
  37. 37. 
    Ziegenhorn HV, Frie KG, Ekanem IO, Ebughe G, Kamate B et al. 2020. Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries. BMC Health Serv. Res. 20:1912
     [Google Scholar]
  38. 38. 
    Martei YM, Pace LE, Brock JE, Shulman LN. 2018. Breast cancer in low- and middle-income countries: why we need pathology capability to solve this challenge. Clin. Lab. Med. 38:1161–73
     [Google Scholar]
  39. 39. 
    Kosack CS, Page AL, Klatser PR 2017. A guide to aid the selection of diagnostic tests. Bull. World Health Organ. 95:9639–45
     [Google Scholar]
  40. 40. 
    Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S 2008. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am. J. Clin. Pathol. 129:4563–70
     [Google Scholar]
  41. 41. 
    Menon MP, Niyonzima N, Gralow J, Orem J 2021. Breast cancer clinical trials: the landscape at the Uganda Cancer Institute and lessons learned. JCO Glob. Oncol. 7:127–32
     [Google Scholar]
  42. 42. 
    Muller BM, Kronenwett R, Hennig G, Euting H, Weber K et al. 2011. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue—a new option for predictive biomarker assessment in breast cancer. Diagn. Mol. Pathol. 20:11–10
     [Google Scholar]
  43. 43. 
    Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:111005–15
     [Google Scholar]
  44. 44. 
    Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. 2007. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J. Mol. Diagnost. 9:2220–27
     [Google Scholar]
  45. 45. 
    Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K et al. 2018. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab. Investig. 98:81076–83
     [Google Scholar]
  46. 46. 
    Wu NC, Wong W, Ho KE, Chu VC, Rizo A et al. 2018. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res. Treat. 172:2327–38
     [Google Scholar]
  47. 47. 
    Cancer Genome Atlas Netw 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:741861–70
     [Google Scholar]
  48. 48. 
    Ma CX, Ellis MJ. 2013. The Cancer Genome Atlas: clinical applications for breast cancer. Oncology 27:121263–69 1274–79
    [Google Scholar]
  49. 49. 
    Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM et al. 2013. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368:131199–209
     [Google Scholar]
  50. 50. 
    Hanna MG, Reuter VE, Ardon O, Kim D, Sirintrapun SJ et al. 2020. Validation of a digital pathology system including remote review during the COVID-19 pandemic. Mod. Pathol. 33:112115–27
     [Google Scholar]
  51. 51. 
    Mpunga T, Hedt-Gauthier BL, Tapela N, Nshimiyimana I, Muvugabigwi G et al. 2016. Implementation and validation of telepathology triage at cancer referral center in rural Rwanda. J. Glob. Oncol. 2:276–82
     [Google Scholar]
  52. 52. 
    Milner DA Jr., Holladay EB. 2018. Laboratories as the core for health systems building. Clin. Lab. Med. 38:11–9
     [Google Scholar]
  53. 53. 
    Fischer MK, Kayembe MK, Scheer AJ, Introcaso CE, Binder SW, Kovarik CL. 2011. Establishing telepathology in Africa: lessons from Botswana. J. Am. Acad. Dermatol. 64:5986–87
     [Google Scholar]
  54. 54. 
    Hashimoto Y, Hatayama Y, Kojima N, Morishita S, Matsumoto S et al. 2016. Development of reverse transcription loop-mediated isothermal amplification for simple and rapid detection of Promyelocytic Leukemia–Retinoic Acid Receptor α mRNA. Yonago Acta Med 59:4262–69
     [Google Scholar]
  55. 55. 
    Stevens WS, Scott LE, Crowe SM. 2010. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J. Infect. Dis. 201:Suppl. 1S16–26
     [Google Scholar]
  56. 56. 
    Sooknanan R, Malek L, Wang XH, Siebert T, Keating A. 1993. Detection and direct sequence identification of BCR-ABL1 mRNA in Ph+ chronic myeloid leukemia. Exp. Hematol. 21:131719–24
     [Google Scholar]
  57. 57. 
    Bobée V, Ruminy P, Marchand V, Viailly PJ, Abdel Sater A et al. 2017. Determination of molecular subtypes of diffuse large B-cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: a CALYM study. J. Mol. Diagn. 19:6892–904
     [Google Scholar]
  58. 58. 
    Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N et al. 2008. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26:3317–25
     [Google Scholar]
  59. 59. 
    Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M et al. 2015. Accurate classification of germinal center B-cell–like/activated B-cell–like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase–multiplex ligation-dependent probe amplification assay: a CALYM study. J. Mol. Diagn. 17:3273–83
     [Google Scholar]
  60. 60. 
    Morgan EA, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D et al. 2016. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Adv 1:184–92
     [Google Scholar]
  61. 61. 
    Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C et al. 2018. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 132:222401–5
     [Google Scholar]
  62. 62. 
    Tzonev S 2018. Fundamentals of counting statistics in digital PCR: I just measured two target copies—what does it mean?. Digital PCR: Methods and Protocols G Karlin-Neumann, F Bizouarn 25–43 New York: Humana:
     [Google Scholar]
  63. 63. 
    Kreutz JE, Wang J, Sheen AM, Thompson AM, Staheli JP et al. 2019. Self-digitization chip for quantitative detection of human papillomavirus gene using digital LAMP. Lab Chip 19:61035–40
     [Google Scholar]
  64. 64. 
    Wang J, Kreutz JE, Thompson AM, Qin Y, Sheen AM et al. 2018. SD-chip enabled quantitative detection of HIV RNA using digital nucleic acid sequence-based amplification (dNASBA). Lab Chip 18:223501–6
     [Google Scholar]
  65. 65. 
    Gansen A, Herrick AM, Dimov IK, Lee LP, Chiu DT 2012. Digital LAMP in a sample self-digitization (SD) chip. Lab. Chip 12:122247–54
     [Google Scholar]
/content/journals/10.1146/annurev-pathol-042320-034052
Loading
Precision Medicine in Low- and Middle-Income Countries
Annual Review of Pathology: Mechanisms of Disease 17, 387 (2022); https://doi.org/10.1146/annurev-pathol-042320-034052
/content/journals/10.1146/annurev-pathol-042320-034052
/content/journals/10.1146/annurev-pathol-042320-034052
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error